$72.63
+0.26 (+0.36%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GEHC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
126 interventional · 45 observational · 1 expanded access · 82 with posted results
Held by 21 tracked-famous managers (Dodge & Cox, HARRIS ASSOCIATES L P, TRIAN FUND MANAGEMENT, L.P., CITADEL ADVISORS LLC, Point72 Asset Management, L.P., +16 more) · FINRA short interest 2.9 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: 2 congress / 5 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)NCT07219238Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC.Open-label · Diagnostic | Phase 2/3 | Recruiting | Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma | 175 | Jun 2029 | ≤ 1,046 d | 2026-06-17 |
| A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour MalignanciesNCT05629689Part A: The incidence of AEs upon causality to the IMPs.Non-randomized · Open-label · Diagnostic | Phase 1 | Recruiting | Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part A, GEH200520 Injection / GEH200521 (18F) Injection - Part B · Diagnostic test: Dynamic and Static - PET/CT scan, Static - PET/CT scan | Malignant Solid Tumor, Oncology | 50 | 2029-03-10 | in 934 d | 2025-11-17 |
| A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult PatientsNCT07472491Phase 2 Primary Endpoint - Overall diagnostic preferenceRandomized · Double-masked · Diagnostic | Phase 2/3 | Recruiting | Drug: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, Gadobutrol · Diagnostic test: MRI Scan | Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion | 640 | 2027-11-30 | in 468 d | 2026-06-29 |
| SpO2 Infant and Pediatric StudyNCT07615738Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 valuesOpen-label · Device feasibility | Not applicable | Not yet recruiting | Device: SpO2 Sensor | SpO2 (Peripheral Oxygen Saturation) Measurement Validation, SpO2 | 180 | 2027-05-31 | in 285 d | 2026-07-01 |
| Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Prospective Double-Scanning StudyNCT07725237observationalNumber of StarGuide GX Data Files Collected | — | Recruiting | Device: StarGuide GX SPECT/CT Scan | SPECT-CT | 30 | Feb 2027 | ≤ 193 d | 2026-08-19 |
| A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric PatientsNCT04604782Occurrence of Adverse Events (AEs) following administration of RegadenosonNon-randomized · Open-label · Diagnostic | Phase 1/2 | Recruiting | Drug: Regadenoson | Myocardial Ischemia, Coronary Artery Disease | 54 | Dec 2026 | ≤ 134 d | 2026-05-06 |
| Non-Invasive Blood Pressure Accuracy Study for Adult Subject PopulationsNCT07628296Primary Outcome MeasureRandomized · Open-label · Diagnostic | Not applicable | Recruiting | Device: NIBP Measurement | Blood Pressure, Blood Pressure Measurement | 130 | 2026-12-31 | in 134 d | 2026-07-08 |
| NIBP Study for Neonate and Pediatric Subject PopulationsNCT07684885Primary Outcome MeasureRandomized · Open-label · Diagnostic | Not applicable | Recruiting | Device: NIBP Measurement | Blood Pressure, Blood Pressure Measurement | 110 | 2026-12-31 | in 134 d | 2026-07-06 |
| NIBP Accuracy Study for Adult Subject PopulationsNCT07697950Primary Outcome MeasureRandomized · Open-label · Diagnostic | Not applicable | Recruiting | Device: NIBP Measurement | Blood Pressure Measurement, Blood Pressure | 130 | 2026-12-31 | in 134 d | 2026-07-13 |
| Portrait Mobile Monitoring Solution V2.0 External EvaluationNCT07309809Collection of user feedback surveys from CliniciansOpen-label · Basic science | Not applicable | Not yet recruiting | Device: Continuous Monitoring | Monitoring | 50 | Oct 2026 | ≤ 73 d | 2026-06-10 |
| NMT EasyFit Sensor and CableNCT07394140Collection of End User Feedback SurveysOpen-label · Device feasibility | Not applicable | Recruiting | Device: Collection of NMT Technology | Neuromuscular Blockade Monitoring, NMT | 30 | 2026-10-31 | in 73 d | 2026-07-08 |
| Data Collection of New Spectral CT Imaging MethodNCT07661706observationalEvaluable Raw Research Scans | — | Recruiting | Device: Research CT | Computed Tomography | 50 | Aug 2026 | ≤ 12 d | 2026-06-22 |
| Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver ImagingNCT06639828Accuracy of Sonazoid-enhanced ultrasound at imaging focal liver lesions during the vascular phase of imagingOpen-label · Diagnostic | Phase 4 | Recruiting | Diagnostic test: Contrast-Enhanced Ultrasound | Focal Liver Lesions | 50 | 2026-07-31 | — | 2026-03-04 |
| Clinical Performance Evaluation of a Diagnostic Ultrasound SystemNCT07066449observationalThe main evaluation indicators include Overall system operation, Reliability, System operability, Overall image quality, etc., and the evaluation results are represented by five grades: Excellent, Very good, Good, Bad, and Very bad. | — | Recruiting | — | Echocardiography | 60 | Apr 2026 | — | 2025-09-19 |
| GSI Cardiac on Revolution Apex - USNCT06702917observationalEvaluable GSI Cardiac Raw Scans | — | Active, not recruiting | Device: GSI Cardiac Scan · Other: Standard of Care CCTA, Research CCTA | Coronary Computed Tomographic Angiography, Myocardial Infarction (MI), Cardiac Catheterization | 50 | 2026-04-03actual | — | 2026-07-15 |
| Point of Care Lung Ultrasound Examination in Patients With Shortness of BreathNCT07046234Cohort 1: % of patient studies composed of images acquired by the THCPs with sufficient quality to make a clinical assessmentNon-randomized · Open-label · Health services research | Not applicable | Enrolling by invitation | Device: Lung ultrasound | Lung Disease, Lung Ultrasound | 150 | Dec 2025 | — | 2025-10-03 |
| Maternal Fetal Device Performance TwinsNCT06835647Collection of Distinct Fetal Heart RateOpen-label · Diagnostic | Not applicable | Recruiting | Device: Investigational Fetal Monitor, Ultrasound Imaging Device | Pregnancy | 15 | 2025-09-30 | — | 2025-07-15 |
| Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary PlaqueNCT06186336observationalData Collection | — | Not yet recruiting | Other: Deep Learning-based Vulnerable Plaque Detection and Assessment Tool | Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome | 200 | Jun 2025 | — | 2025-01-07 |
| CARESCAPE Monitoring Systems ME StudyNCT07024459Clinical evaluation of the performance and usabilityOpen-label · Diagnostic | Not applicable | Enrolling by invitation | Device: Monitoring | Surgery, Intensive Care | 80 | 2025-06-30 | — | 2025-06-17 |
| Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast CancerNCT05486182To assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.Open-label · Diagnostic | Phase 4 | Active, not recruiting | Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT | Metastatic Breast Cancer | 153 | 2025-04-18actual | — | 2025-08-14 |
| Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast CancerNCT05634954Specific absorbed dose to the target lesions, specific absorbed dose per organ, and total effective dose of [18F]GEH121224.Non-randomized · Open-label · Diagnostic | Phase 1 | Withdrawnsponsor's stated reason: Business Decision | Drug: GEH121224 (18F) Injection · Diagnostic test: Dynamic and Static - PET/CT Scan, Static - PET/CT Scan | Breast Cancer | 0 | Dec 2026 | ≤ 134 d | 2025-10-23 |
| Clinical Feasibility and Evaluation of Silicon Photon Counting CTNCT05838482observationalData Collection | — | Completed | Device: CT Photon-Counting | CT Photon-Counting | 45 | 2026-04-30actual | — | 2026-06-17 |
| Next Generation CT SystemNCT06769594observationalData Collection | — | Completed | Device: Investigational CT Scan | Computed Tomography | 64 | 2026-03-06actual | — | 2026-04-29 |
| Clinical Data Collection On Advanced CT SystemNCT05835284observationalData Collection | — | Completed | Device: Investigational Edge-on Silicon Photon Counting CT device | CT Photon Counting | 76 | 2026-02-19actual | — | 2026-04-27 |
| A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy VolunteersNCT06398730Incidence of all TEAEsNon-randomized · Open-label · Diagnostic | Phase 1 | Completed | Drug: GEH200520 Injection and GEH200521 (18F) Injection · Diagnostic test: Static - PET/CT scan | Healthy Volunteers | 22 | 2026-02-19actual | — | 2026-03-06 |
| NIBP Accuracy Study for AdultNCT07684859observationalCollection of Non-Invasive Blood Pressures and Invasive Blood Pressures | — | Withdrawnsponsor's stated reason: duplicate record | — | Blood Pressure, Blood Pressure Measurement | 0 | 2025-09-30 | — | 2026-07-06 |
| NIBP Cuff Comparison StudyNCT07024472observationalPrimary Outcome Measure | — | Completed | — | Blood Pressure, Blood Pressure Measurement | 32 | 2025-06-23actual | — | 2025-07-03 |
| Evaluation of the Goldcrest Patch PerformanceNCT06355453observationalCollection of Skin Integrity Quality | — | Completed | Device: Goldcrest Patch and Three Patch Coupons, Goldcrest Patch and Novii Patch | Fetal Monitoring | 38 | 2025-03-31actual | — | 2025-07-14 |
| Maternal Fetal Device Performance SingletonNCT06726343results2026-01-07Success Rate Calculated Based on Collection of Fetal Heart Rate Data From Investigational Devices on Subjects Enrolled in Each Gestational Age GroupNon-randomized · Open-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Fetal Monitoring Device, Investigational Fetal Monitoring Device | Pregnancy | 30 | 2024-12-23actual | — | 2026-01-07 |
| Carbon Dioxide InvestigationNCT06715410Collection of dataOpen-label · Diagnostic | Not applicable | Completed | Device: CO2 | Intubation, Tracheostomy, Laryngeal Mask | 42 | 2024-09-16actual | — | 2024-12-04 |
| Pediatric Risk of Hypothyroidism With Iodinated Contrast MediaNCT03631771The proportion of subjects who develop hypothyroidism post-ICM.Open-label · Other | Phase 4 | Withdrawnsponsor's stated reason: It was determined that a study is no longer required because the clinical question posed by the study has been answered through published literature | Drug: Iohexol, Iodixanol, Iopromide, Ioversol | Hypothyroidism | 0 | Aug 2024 | — | 2022-04-20 |
| Feasibility Study Of Ambulatory Monitoring SystemNCT04959136User feedbackOpen-label · Other | Not applicable | Unknown status | Device: Ambulatory Monitoring Solution | Patient Monitoring | 300 | 2024-08-31 | — | 2021-07-13 |
| [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorNCT04265209Sensitivity and specificity by visual analysisRandomized · Single-masked · Diagnostic | Phase 3 | Completed | Drug: SPECT, PET | Parkinson Disease, Essential Tremor | 152 | 2024-08-02actual | — | 2025-11-17 |
| Altropane Dose for Imaging Patients With Suspected Parkinson's DiseaseNCT05636852results2025-07-15Striatal Visualization: Percentage of Participants With Correct Majority Classifications of 5-mCi Altropane Images as Determined by 5 Independent Blinded ReadersOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: Altropane (123I) Injection | Parkinson Disease, Movement Disorders | 15 | 2024-06-08actual | — | 2025-07-15 |
| Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer PatientsNCT05068726observationalEvaluate change in therapeutic management plan assessed by comparing pre/post-Cerianna PET/CT treatment selection (based on comparison of the initial management plan and post-Cerianna PET/CT management plan evaluated within 3 weeks). | — | Terminatedsponsor's stated reason: Sponsor discretion (low recruitment rate) | Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT | Metastatic Breast Cancer | 51 | 2024-06-01actual | — | 2024-07-31 |
| Clinical Data Collection in Breast Tomosynthesis (COBRIS)NCT05914168Data CollectionOpen-label · Other | Not applicable | Unknown status | Device: Breast Tomosynthesis | Breast Cancer | 150 | Feb 2024 | — | 2023-06-22 |
| Wireless Disposable SpO2 Sensor Hypoxia TestingNCT06211530results2025-04-30Collection of Subject SpO2 Percentage Sensor Data With Transfer Standard Measurements for ValidationOpen-label · Device feasibilityStudy Protocol and Informed Consent Form ↗ | Not applicable | Completed | Device: SpO2 Sensor Testing | SpO2, Peripheral Oxygen Saturation Measurement | 32 | 2024-02-08actual | — | 2025-04-30 |
| Clinical Data Collection and Evaluation of ECG-Less Cardiac CTNCT05949138observationalData Collection | — | Completed | Device: ECG-Less Cardiac CT using SmartPhase | Cardiac CT | 56 | 2023-11-01actual | — | 2024-06-07 |
| Dual Energy Cardiac CT Data Collection and EvaluationNCT05171764observationalCollect Data | — | Completed | Device: Additional Gemstone Spectral Imaging (GSI) cardiac scan | Cardiovascular Diseases | 30 | 2023-10-13actual | — | 2023-12-18 |
| Data Collection for Validation of an NIBP Algorithm in Pregnant WomenNCT05789849Collection of per subject NIBP measurementsOpen-label · Other | Not applicable | Unknown status | Device: Collecting blood pressure measurements with noninvasive blood pressure device | Blood Pressure | 170 | Sep 2023 | — | 2023-03-29 |
| Study to Determine Safety and Dosage of OPTISON in Pediatric ParticipantsNCT03740997results2024-05-17Mean Total Visualization Score of Qualitative Endocardial Border Delineation (EBD) of the 12 Segments of the Left Ventricle (LV) Wall in Standard Apical 4-chamber (A4C) and Apical 2-chamber (A2C)Non-randomized · Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Optison | Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality | 39 | 2023-03-30actual | — | 2024-05-17 |
| Spectral CT With Advanced CT TechnologyNCT04781296Evaluate feasibility of the photon-counting CT in a clinical setting.Open-label · Device feasibility | Not applicable | Completed | Device: CT with a photon-counting detector | CT Photon-Counting | 30 | 2022-12-14actual | — | 2025-12-04 |
| Safety and Pharmacokinetics of GEH200486 in Healthy VolunteersNCT05569278Collection of occurrence of IMP-related SAEsNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: GE200486 0.5M Injection | Pharmacokinetics | 15 | 2022-11-29actual | — | 2023-07-06 |
| Evaluation of a New Generation of PET-CT OMNINCT05154877observationalEvaluation | — | Completed | Device: OMNI PET/CT Scan | Oncology | 45 | 2022-08-30actual | — | 2024-06-07 |
| GE CVUS Device EvaluationNCT05340244results2022-11-23Number of User Feedback SurveysOpen-label · OtherStudy Protocol ↗ | Not applicable | Completed | Device: Investigational ultrasound exam | Echocardiography | 8 | 2022-07-26actual | — | 2023-01-10 |
| Demonstration Of A Next Generation PET CT SystemNCT05122715Evaluation- Likert ScaleRandomized · Open-label · Diagnostic | Not applicable | Unknown status | Device: Additional PET/CT Scan | Oncology | 70 | 2022-07-01 | — | 2022-05-23 |
| A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing ProcessesNCT04594941results2023-08-01Intra-reader Difference of Summed Rest Score (SRS) for Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI)Randomized · Double-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Flurpiridaz (18F) Injection | Coronary Artery Disease (CAD), Ischemic Heart Disease | 38 | 2022-05-26actual | — | 2023-08-01 |
| An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)NCT03354273results2023-07-12Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac CatheterizationOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: PET MPI, SPECT MPI, Pharmacological stress agents | Coronary Artery Disease (CAD) | 730 | 2022-05-05actual | — | 2023-07-12 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsNCT04193527results2023-10-16Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT ImagesOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: DaTSCAN™ Ioflupane (123I) Injection | Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Essential Tremor | 172 | 2021-12-20actual | — | 2023-10-16 |
| Development Of Medical Ultrasound Systems, Accessories, And Components - GE BangaloreNCT02946242Completion of diagnostic ultrasound examOpen-label · DiagnosticStudy Protocol ↗ | Not applicable | Completed | Device: Ultrasound Exam | Ultrasound Exams | 39 | 2021-12-17actual | — | 2023-05-01 |
| A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in EuropeNCT04773015results2024-10-10observationalAccuracy of VIZAMYL™ PET Image Interpretations Made by Clinical ReadersStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | — | Cognitive Impairment | 227 | 2021-12-07actual | — | 2024-10-10 |
| AMS Evaluation StudyNCT04472208User feedback survey about the use of the Ambulatory Monitoring SolutionOpen-label · Other | Not applicable | Completed | Device: Ambulatory monitoring solution | Patient Monitoring | 34 | 2021-10-14actual | — | 2021-11-03 |
| A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.NCT04564092results2023-08-02Number of Participants With Adverse Events (AEs)Open-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: DaTSCAN™ Ioflupane (123I) Injection | Healthy Subjects (HS) | 9 | 2021-09-04actual | — | 2023-08-02 |
| Use of Digital Tomosynthesis for Detection and Case Management of Scaphoid and Distal Radius Fractures: A VolumeRAD Data Collection StudyNCT03856450Number of X-ray ImagesNon-randomized · Open-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Unknown status | Device: DTS, X-ray, MRI or CT | Distal Radius Fracture, Scaphoid Fracture | 140 | 2021-09-01 | — | 2020-09-30 |
| Automated Breast Ultrasound as an Adjunct to Screening Digital Breast TomosynthesisNCT03616457observationalCancer Detection Rate | — | Withdrawnsponsor's stated reason: Change in business need. | Device: Automated Breast Ultrasound (ABUS) | Breast Cancer | 0 | Aug 2021 | — | 2018-10-26 |
| Evaluation of Continuous Non Invasive Blood Pressure With Adult VolunteersNCT04876664Data collection of NIBP measurementOpen-label · Diagnostic | Not applicable | Unknown status | Device: measuring blood pressure with noninvasive blood pressure device | Blood Pressure | 12 | 2021-07-31 | — | 2021-05-06 |
| Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumNCT03671603observationalAssessment of the Incidence Rate of AKI in STEMI Participants Undergoing Primary PCI Using Visipaque | — | Completed | Drug: Iodixanol | Coronary Artery Disease, ST-segment Elevation Myocardial Infarction | 2,755 | 2021-06-07actual | — | 2022-01-11 |
| Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) ExaminationNCT03455283observationalPattern of Use of GBCAs in Magnetic Resonance Imaging (MRI) Centres | — | Completed | Drug: Clariscan · Other: Gadolinium-Based Contrast Agents | Magnetic Resonance Imaging (MRI) | 2,118 | 2019-11-11actual | — | 2019-12-04 |
| U-TruSignal SpO2 Testing in NeonatesNCT03383757results2020-12-04Accuracy Root Mean Square (ARMS) Per Data PairOpen-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: SpO2 Sensor application & blood draw | Pulse Oximetry | 117 | 2019-11-01actual | — | 2020-12-04 |
| Performance of the Monica Novii Wireless Patch System in Pre-term LaborNCT03057275observationalFHR Percent Agreement | — | Completed | Device: Abdominal fetal/maternal monitoring | Premature Labor | 47 | 2019-09-20actual | — | 2021-02-09 |
| Measurement of NonInvasive Blood Pressure in Neonates Through Adults and Special PopulationsNCT02125331results2020-06-11observationalNumber of Participants With Accurate NIBP Measurements as Confirmed by IBP MeasurementsStudy Protocol and Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: Data collection requirment complete | Procedure: Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM) | Blood Pressure | 83 | Mar 2019actual | — | 2020-06-11 |
| Automated Breast Ultrasound Case Collection RegistryNCT03417024results2019-09-09observationalNumber of Complete Breast Imaging DatasetsStudy Protocol ↗ | — | Terminatedsponsor's stated reason: Change in business strategy | Device: Automated Breast Ultrasound, Digital Breast Tomosynthesis | Breast Cancer | 13 | 2019-01-25actual | — | 2019-09-09 |
| A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney DiseaseNCT03119662results2019-12-17Assessment of the Incidence of Acute Kidney Injury (AKI) Stage >=1 Per Acute Kidney Injury Network (AKIN) Serum Creatinine (SCr) CriteriaRandomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: The trial was discontinued due to a lower than anticipated recruitment rate. The decision has not been made due to any safety reasons. | Drug: Visipaque, Placebos | Chronic Kidney Diseases | 4 | 2018-09-13actual | — | 2019-12-17 |
| Multi-site Anesthesia Randomized Controlled STudy of End Tidal Control Compared to Conventional Anesthesia ResultsNCT02972892results2022-11-02Percent Duration Without Large Deviation of End-Tidal Anesthetic Agent (EtAA) Based on Extraction Algorithm (ALG)Randomized · Single-masked · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Et Control Feature, Conventional Fresh Gas | Et Control Performance in Adult Population Surgery | 248 | 2018-09-05actual | — | 2022-11-02 |
| Clinical Evaluation of the OEC Elite MD for Vascular Procedures at Hamilton General HospitalNCT03417713results2018-11-29observationalImage Guidance Adequacy Collected Via Survey QuestionnaireStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Fluoroscopic imaging with the OEC Elite Device | Interventional Vascular Conditions | 33 | 2018-05-15actual | — | 2018-11-29 |
| International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical DeviceNCT02656329results2019-05-22All-cause MortalityRandomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor discretion (low recruitment rate) | Drug: Iobenguane I -123 Injection, Thyroid blocking, Iobenguane I -123 Injection · Device: Implantable Cardioverter Defibrillator, Implantable Cardioverter Defibrillator | Heart Failure | 395 | 2018-05-04actual | — | 2019-05-22 |
| Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2NCT02556177results2019-09-10MRI Image Data SetsNon-randomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Procedure: MRI | Concussion, Traumatic Brain Injury | 477 | 2018-01-31actual | — | 2019-09-10 |
| Venue Ultrasound Evaluation - IsraelNCT03861663Obtain Image sets using Ultrasound Venue SystemOpen-label · Device feasibility | Not applicable | Completed | Device: Ultrasound | Ultrasound Exam in Emergency/Medical Care | 53 | 2018-01-29actual | — | 2019-03-04 |
| Patient-Assisted Compression in 3D - Impact on Image Quality and WorkflowNCT03456427results2019-04-05Percentage of Acceptable Overall Image QualityOpen-label · Device feasibilityStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Patient-Assisted Compression (PAC), Technologist-Controlled (TC) Compression | Breast Cancer | 36 | 2018-01-09actual | — | 2019-04-05 |
| Vscan Access R2 Feasibility EvaluationNCT03617419results2019-07-11Difference in Fetal Heart Rate as Measured by VScan Access R2 and CorometricsOpen-label · Device feasibilityStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: GE VScan Access R2 Ultrasound System, GE Corometrics 170 Series Fetal Monitor, GE Corometrics 170 Series Fetal Monitor | Gather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd Trimester | 16 | 2017-11-20actual | — | 2019-07-11 |
| Clinical Evaluation Of MP26 Features in AdultsNCT02927327results2018-12-06Diagnostic Image QualityNon-randomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Zero Echo Time (ZTE) scan for head attenuation, Q.Static (Q. MRAC) for respiratory motion correction | Brain Imaging, Whole Body Imaging | 61 | 2017-09-20actual | — | 2018-12-06 |
| Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)NCT02324205results2019-02-26Number of Participants With DBT, FFDM and Biopsy Specimens Collected.Open-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor met enroll. need for planned second study before meeting enroll. ceiling in protocol | Device: DBT and FFDM | Breast Cancer, Tumors, Breast | 196 | 2017-08-29actual | — | 2019-02-26 |
| Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly Sheffield)NCT02785588results2019-09-13Image Diagnostic Quality for Phase 1Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: 3.0 T Neonatal MRI scanner | Neonatal Neuroimaging | 54 | 2017-08-20actual | — | 2019-09-13 |
| Clinical Evaluation of the Next Generation Venue Ultrasound System, Components, and Accessories - CanadaNCT03653572Obtain Image sets using Ultrasound Venue SystemOpen-label · Device feasibility | Not applicable | Completed | Device: Ultrasound exam | Ultrasound Use in Emergency/Medical Care | 35 | 2017-08-01actual | — | 2018-08-31 |
| Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to MammographyNCT02306265results2019-01-29Number of Participants With Imaging Data CollectedOpen-label · ScreeningStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: FFDM, DBT | Breast Cancer, Tumors, Breast, Cancer Screening | 250 | 2017-07-07actual | — | 2019-01-29 |
| Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy SystemNCT03096483results2019-03-27Imaging Guidance Adequacy Assessed by Number of QuestionnairesOpen-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor determination | Device: OEC Elite system | Interventional Vascular Conditions | 12 | 2017-07-07actual | — | 2019-03-27 |
| Patient-Assisted Compression - Impact on Image Quality and WorkflowNCT03196635results2018-08-31Number of Subjects With Acceptable Overall Clinical Image Quality for Patient-assisted (PA) and Technologist-controlled (TC) Image SetsOpen-label · ScreeningStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Patient-Assisted (PA) Breast Compression, Technologist-Controlled (TC) Breast Compression | Breast Cancer | 31 | 2017-06-29actual | — | 2018-08-31 |
| Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to MammographyNCT02540083results2019-02-05Number of Participants With DBT, FFDM and Biopsy Specimens CollectedOpen-label · DiagnosticStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor has obtained sufficient case load prematurely. | Device: DBT and FFDM | Breast Cancer, Tumors, Breast | 94 | 2017-05-30actual | — | 2019-02-05 |
| Accuracy and Reliability of Novii: Fetal Heart Rate (FHR), Maternal Heart Rate (MHR) and Uterine Contraction (UA) Compared With Doppler, Scalp Fetal Scalp Electrode (FSE), Tocodynamometer (TOCO) and Intra Uterine Pressure Catheter (IUPC)NCT03409146observationalFetal Heart Rate (FHR) Positive Percentage Agreement (PPA) | — | Completed | Device: Monica Novii Wireless Patch System | Term Labour | 80 | 2017-02-13actual | — | 2021-02-09 |
| Comparison of Adequacy of Anesthesia Monitoring With Standard Clinical Practice During Routine General AnesthesiaNCT01928875Incidence of hemodynamic instabilityRandomized · Single-masked · Treatment | Not applicable | Completed | Device: AoA Monitoring, Routine (Standard) Anesthesia Monitoring | Surgical Procedure, Unspecified | 496 | 2017-02-01actual | — | 2017-05-01 |
| Data Collection for Next Generation Ultrasound Technology DevelopmentNCT02946229results2018-11-02Number of Diagnostic Ultrasound ExamsOpen-label · Device feasibility | Not applicable | Completed | Device: Ultrasound scan | Endstage Renal Disease | 142 | 2016-12-06actual | — | 2018-11-02 |
| Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care UnitNCT02232009results2019-01-30Summary Rates of Adverse EventsOpen-label · Other | Not applicable | Terminatedsponsor's stated reason: Slow/low enrollment | Device: 3.0 T Neonatal MRI Scanner | Image Evaluation | 9 | 2016-11-30actual | — | 2019-01-30 |
| Clinical Evaluation of a Dual Energy CT SystemNCT02731937Raw CT Scan DataOpen-label · Diagnostic | Not applicable | Completed | Device: GE Healthcare Revolution CT Scanner (CT Scanner) | General CT Imaging | 48 | Jul 2016actual | — | 2017-05-08 |
| Non-invasive Quantification of Liver Iron With MRINCT02425956results2017-07-24Per Subject Evaluable DICOM Data Sets From Liver MRIOpen-label · Diagnostic | Not applicable | Completed | Device: GE Optima/Discovery® MRI data of the liver | Iron Overload | 21 | 2016-06-30actual | — | 2017-07-24 |
| Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).NCT01738347Recording the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.Open-label · Other | Phase 1 | Completed | Drug: Arm 1 - GEH120714 (18F) Injection | Relapsing-remitting Multiple Sclerosis (rrMS) | 30 | May 2016actual | — | 2017-02-24 |
| Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)NCT01952678results2018-08-02observationalPositive Percent Agreement of Blinded Visual Assessment of Each Participant's DaTscan Image - Intent-to-diagnose (ITD) Population | — | Completed | Other: DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants | Essential Tremor, Parkinson's Disease | 204 | May 2016actual | — | 2018-08-02 |
| Image Quality Assessment for Screening and Diagnostic MammographyNCT02786004results2017-07-21Number of Participants With Acceptable Overall Clinical Image QualityNon-randomized · Open-label · Diagnostic | Not applicable | Completed | Device: Full Field Digital Mammography, Digital Breast Tomosynthesis | Breast Health | 24 | May 2016actual | — | 2018-11-07 |
| Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical SettingNCT03229772Diagnostic Image QualityOpen-label · Other | Not applicable | Completed | Device: Discovery NM/CT 670 CZT Imaging Scan | Cancer | 19 | Feb 2016actual | — | 2017-07-26 |
| Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR ImagesNCT02596854results2017-11-06Mean Diagnostic Image Quality Difference Between Conventional Versus Synthetic MR Utilizing a 5 Point Likert ScaleOpen-label · Diagnostic | Not applicable | Completed | Device: Neurological MRI | Clinical Indication for Brain MRI | 117 | Jan 2016actual | — | 2018-06-18 |
| Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense BreastsNCT02042456observationalAbnormal interpretation rate | — | Terminatedsponsor's stated reason: Change in study staff at the site, change in Sponsor direction | Device: Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound, Full Field Digital Mammography | Breast Cancer | 124 | Jul 2015actual | — | 2015-10-20 |
| Advanced MRI Applications for Mild Traumatic Brain InjuryNCT02070588results2017-07-21mTBI Progression Indicated by Clinical Neurological Characteristics, MRI Images, and Quantitative MRI Data From Novel SoftwareNon-randomized · Open-label · Other | Not applicable | Terminatedsponsor's stated reason: Sponsor terminated early as moving to a new larger study program | Device: MRI | Mild Traumatic Brain Injury, Traumatic Brain Injury | 112 | Jun 2015actual | — | 2017-07-21 |
| Advanced MRI Applications for Mild Traumatic Brain Injury - UCSFNCT02141360results2017-07-24mTBI Progression Indicated by Clinical Neurological Characteristics, MRI Images, and Quantitative MRI Data From Novel SoftwareNon-randomized · Open-label · Basic science | Not applicable | Terminatedsponsor's stated reason: Sponser terminated early to start a larger feasability study | Device: MRI Diagnostic | Traumatic Brain Injury | 17 | May 2015actual | — | 2017-07-24 |
| TBI MR Study 3 Houston MethodistNCT02218216results2017-07-24mTBI Progression Indicated by Clinical Neurological Characteristics, MRI Images, and Quantitative MRI Data From Novel SoftwareNon-randomized · Open-label · Basic science | Not applicable | Terminatedsponsor's stated reason: Sponsor terminated study early to start a larger feasability study | Device: MRI Diagnostic | Traumatic Brain Injury | 16 | May 2015actual | — | 2017-07-24 |
| An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound ImagingNCT03335566results2018-08-27Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of TruthRandomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: Sonazoid™, SonoVue® | Liver Lesions | 424 | 2015-04-09actual | — | 2018-10-31 |
| Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and ComponentsNCT01992354results2019-03-05PET/MR Scan ObtainedOpen-label · Other | Not applicable | Terminatedsponsor's stated reason: Low enrollment | Device: PET MR Device | Indication for a PET CT Exam | 4 | Jan 2015actual | — | 2019-03-19 |
| Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.NCT02127307results2017-03-28observationalRelationship Between the Occurrence of Death and 123I-mIBG Uptake on Planar Scintigraphy With Heart to Mediastinum (H/M) Ratio of <1.60 vs H/M ≥1.60 | — | Completed | — | Heart Failure (HF) | 964 | Dec 2014actual | — | 2017-03-28 |
| A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy VolunteersNCT03340870Area Under the Concentration Versus Time Curve from Time Zero to the Last Time- Point (AUC 0-last), AUC from Time Zero to Infinity (AUC0-infinity∞) After Single Dose in BloodNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: Sonazoid™ | Healthy | 16 | 2014-11-20actual | — | 2017-11-14 |
| Clinical Evaluation of an Integrated PET/MRI SystemNCT02071706results2019-04-08Number Usable PET/MRI Image SetsOpen-label · Other | Not applicable | Completed | Device: PET/MRI system | Subjects With Clinical Indication for PET/CT | 62 | Aug 2014actual | — | 2019-04-08 |
| Comparison of 18F FDG PET/CT TO PET MRINCT01986985results2015-05-04PET/MR Images Clinical UsefulnessOpen-label | Not applicable | Completed | Device: PET/MRI system | Any Condition With a Clinical Indication for PET/CT Exam | 58 | Jun 2014actual | — | 2016-03-07 |
| Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.NCT01936649results2015-01-26To Assess Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake in Heart Failure (HF) Participants on Planar Imaging at 3 Hours 50 Minutes Following I.V. Injection of AdreView (Iobenguane I 123 Injection)Open-label · Diagnostic | Phase 4 | Completed | Drug: AdreView (Iobenguane I 123 Injection) | Heart Failure (HF), Ventricular Dysfunction, Left | 63 | Feb 2014actual | — | 2016-12-08 |
| Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined PostmortemNCT02090855results2014-08-27observationalThe Number of Abnormal Blinded Visual PET Image Interpretations. | — | Completed | — | Cognitive Impairment | 108 | Feb 2014actual | — | 2017-03-27 |
| Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's DiseaseNCT01028053results2014-09-11Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.Open-label · Diagnostic | Phase 3 | Completed | Drug: Flutemetamol (18F) Injection | Mild Cognitive Impairment, Alzheimer's Disease | 365 | Jan 2014actual | — | 2014-09-11 |
| SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm EnhancementNCT01482325results2016-09-30Data Collection for Engineering DevelopmentOpen-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: The business decided not to pursue the study at this time. | Device: Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor | Blood Pressure (Low, Normal, High) | 31 | Dec 2013actual | — | 2016-09-30 |
| Clinical Evaluation for General Electric (GE) CT SystemNCT01909180results2016-04-22Image QualityNon-randomized · Open-label · Diagnostic | Not applicable | Completed | Device: Revolution CT Scanner | CT Scanners X Ray | 49 | Nov 2013actual | — | 2016-04-22 |
| A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe EssentialNCT01885143observationalDBT in Senographe Essential is of acceptable quality according to FDA criteria | — | Completed | Radiation: Digital Breast Tomosynthesis | Image Correction | 80 | Oct 2013actual | — | 2014-12-02 |
| MRI Scanning of People With MR Safe Orthopedic Implants That Are Made of MetalNCT01570543observationalImage quality of images that are obtained from scanning subjects who have metallic MR Safe or MR Conditional implants, will be evaluated on a pass/fail basis. | — | Withdrawnsponsor's stated reason: After over a year no subjects were identified | — | Implants | 0 | Sep 2013actual | — | 2013-10-01 |
| Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)NCT00908310results2014-07-17Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in Order to Assess the Risk for Developing Nephrogenic Systemic Fibrosis (NSF).Open-label | Phase 4 | Completed | Drug: Omniscan | Chronic Kidney Disease, Renal Insufficiency | 213 | Jun 2013actual | — | 2014-07-17 |
| Comparison of PET Amyloid Imaging in Japanese and Western SubjectsNCT02813070results2017-06-05Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese ReadersNon-randomized · Open-label · Diagnostic | Phase 2 | Completed | Drug: [18F] Flutemetamol | Mild Cognitive Impairment, Alzheimer's Disease, Healthy | 70 | May 2013actual | — | 2017-06-05 |
| Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral ArteriographyNCT01475097results2014-04-15Subjects Experiencing Discomfort When Undergoing Peripheral ArteriographyRandomized · Double-masked | Phase 4 | Completed | Drug: Iodixanol, Iopamidol | Drug Safety | 255 | Feb 2013actual | — | 2014-06-11 |
| Magnetic Resonance Imaging Using Innovative Pulse SequencesNCT01724216results2014-09-02Number of Head Images Successfully CollectedOpen-label | Not applicable | Completed | Device: pulse sequences | Clinical Indication for a Head MRI | 11 | Feb 2013actual | — | 2015-11-18 |
| SpO2 System Accuracy Testing With Different SensorsNCT01613222results2019-02-05Accuracy Root Mean Square (ARMS)Open-label · Other | Not applicable | Completed | Device: Pulse oximetry | Pulse Oximetry | 63 | 2013-02-15actual | — | 2019-02-05 |
| Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary ProcedureNCT01252810results2014-05-02Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.Randomized · Double-masked · Diagnostic | Phase 2 | Completed | Drug: GE-145 | Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure | 284 | Dec 2012actual | — | 2018-08-29 |
| DXA Precision and Accuracy Comparison StudyNCT01530477results2014-09-25Short Term Precision Comparison Across Three DXA DevicesNon-randomized · Open-label · Screening | Not applicable | Terminatedsponsor's stated reason: Early termination due to inability to meet enrollment for \>350lb weight class | Device: Lunar Prodigy (GEHC), Lunar iDXA (GEHC), Discovery A (Hologic | Osteopenia | 82 | Dec 2012actual | — | 2016-09-16 |
| Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) ImagesNCT01672827results2013-12-19Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.Single-masked · Diagnostic | Phase 3 | Completed | Drug: [18F]Flutemetamol | Alzheimer's Disease, Mild Cognitive Impairment | 276 | Aug 2012actual | — | 2014-01-24 |
| Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy VolunteersNCT01672996results2014-03-03Radiographic Densities at Selected Regions in Contrast-enhanced CT Examination by Location (Abdominal Aorta), kVp 80 and Contrast Type (Ioforminol vs Iopamidol), Concentration (Ioforminol 160 or 200) and Dose Levels (1.0, 1.5, and 2.0mL/kg).Randomized · Open-label · Diagnostic | Phase 1/2 | Completed | Drug: Ioforminol 160 mgI/mL, Ioforminol 200 mgI/mL, Iopamidol 300 mgI/mL | Healthy | 66 | Aug 2012actual | — | 2014-05-29 |
| A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging SystemNCT01076296results2016-03-07observationalPercentage of Correct Diagnosis | — | Completed | — | Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases | 1,000 | Jul 2012actual | — | 2016-03-07 |
| Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast CancerNCT01303419results2019-04-10Completion of CE-BMRI and DE-CEDMOpen-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: Sponsor determined there was sufficient material collected to answer the study questions. | Device: CE-BMRI, DE-CEDM | Breast Cancer | 224 | 2012-06-30actual | — | 2019-04-10 |
| Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery DiseaseNCT01394926results2014-04-16Finding the Optimal Dose of Optison From 3 Different Dose Levels; 0.15mL, 0.5mL, and 1.5mL.Non-randomized · Open-label · Diagnostic | Phase 2 | Terminatedsponsor's stated reason: Lack of Subject Recruitment | Drug: Optison | Carotid Artery Disease | 21 | Jun 2012actual | — | 2014-05-02 |
| Pilot Study of Model Based Iterative Reconstruction Using 64-SliceNCT01431378observationalEvidence for reduced x-ray radiation exposure for applicable patient indications | — | Terminatedsponsor's stated reason: Feasibility study, sufficient amount of data collected. | — | Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis | 92 | May 2012actual | — | 2015-12-11 |
| GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate CancerNCT01176513results2013-11-21To Assess the Magnitude of Uptake and Retention of GE-148 (18F) Injection in Malignant Prostate Tumors, Non-malignant Prostate Pathology, and Regions of Normal Prostate Tissue in Subjects With Prostate Cancer, Using PET/CT Imaging.Non-randomized · Open-label · Diagnostic | Phase 2 | Terminatedsponsor's stated reason: Lack of Subject enrollment | Drug: GE-148 (18F) | Prostate Cancer | 25 | Mar 2012actual | — | 2014-02-14 |
| Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection FractionNCT01440517results2014-02-04Evidence of Active Myocardial Angiogenesis/RemodelingOpen-label · Diagnostic | Phase 2 | Terminatedsponsor's stated reason: Lack of Subject Recruitment | Drug: Tc99m-Maraciclatide | Diabetes Mellitus, Heart Failure | 4 | Mar 2012actual | — | 2014-02-04 |
| B40 Non-Invasive Blood Pressure Equivalency StudyNCT01546285results2013-06-21Difference Between the B40 Monitor and Reference Device DINAMAP PRO1000 on NIBP MeasurementsOpen-label · Diagnostic | Not applicable | Completed | Device: Blood Pressure Readings on B40 Patient Monitor | Blood Pressure | 66 | Mar 2012actual | — | 2013-06-21 |
| Prevalence of Sleep Disordered BreathingNCT01011647observationalSleep disordered breathing was detected either by signals obtained from patient monitoring or by standard approaches by the site. | — | Terminatedsponsor's stated reason: Inadequate recruitment | — | Unstable Angina, Acute Myocardial Infarction, Congestive Heart Failure | 53 | Dec 2011actual | — | 2012-01-05 |
| Accuracy Study of a Non-Invasive Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood PressureNCT01485120results2019-05-31Performance Comparison: NIBP Forearm Cuff Using SuperStat Algorithm vs. Invasive Radial Blood Pressure ReadingOpen-label · Diagnostic | Not applicable | Completed | Device: BP monitoring using two methods | Blood Pressure | 34 | Dec 2011actual | — | 2019-05-31 |
| Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem LevelsNCT01165554results2013-12-04The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.Open-label · Diagnostic | Phase 3 | Completed | Drug: [18F] Flutemetamol | Brain Fibrillarab Levels | 203 | Nov 2011actual | — | 2013-12-04 |
| NICU-TECH RM9L-RS Probe ME Feasibility StudyNCT01181596results2019-08-06observationalParticipants That Fulfilled All Study Procedures. | — | Terminatedsponsor's stated reason: Images not adequate to visualize catheter penetration or obtain measurements | — | Neonates | 31 | Nov 2011actual | — | 2019-08-06 |
| A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and AngiogenesisNCT00565721results2014-08-08Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and αvβ3 Optical Density)Open-label · Diagnostic | Phase 2 | Completed | Drug: Fluciclatide Injection - (AH111585 (F18)) | High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma | 33 | Oct 2011actual | — | 2014-08-18 |
| Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/PelvisNCT01376089results2013-12-19Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.Randomized · Double-masked | Phase 4 | Completed | Drug: Iodixanol, Iopamidol | Patient Comfort and Safety | 304 | Oct 2011actual | — | 2013-12-19 |
| Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) InjectionNCT00918281results2014-06-09Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F) Injection Via PET Imaging.Open-label · Diagnostic | Phase 2 | Completed | Drug: Fluciclatide Injection | Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer | 70 | Sep 2011actual | — | 2014-06-09 |
| Evaluation of Orthopedic Knee Measurement Using Lunar iDXANCT01348958Efficacy of Lunar orthopedic knee software.Open-label · Diagnostic | Not applicable | Completed | Device: iDXA knee software | Hemi Knee Arthroplasty, Patello-femoral Osteoarthritis | 36 | Sep 2011actual | — | 2017-06-22 |
| Recurrence of Bladder Cancer After Transurethral Resection With HexvixNCT00785694Rate of bladder cancer recurrenceRandomized · Open-label · Diagnostic | Phase 4 | Withdrawnsponsor's stated reason: Rejected ethics approval in UK and Holland | Drug: hexaminolevulinate | Bladder Cancer | 0 | Aug 2011actual | — | 2015-04-24 |
| Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed TomographyNCT00209417results2014-10-10Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.Randomized · Triple-masked · Diagnostic | Phase 4 | Terminatedsponsor's stated reason: Supported by preliminary interim analysis. Not based on any safety signals in study or any quality issues that could affect efficacy of the product. | Drug: Iodixanol 320-Arm 1, Iopamidol 300-Arm 2 | Renal Insufficiency, Diabetes Mellitus | 656 | May 2011actual | — | 2014-10-17 |
| Radiant Warmer TrialNCT01011855Abdominal skin surface temperatures and axillary temperatures under 3 radiant warmer conditions as measured by skin thermistors and infrared thermography (IRT).Randomized · Open-label · Supportive care | Not applicable | Withdrawnsponsor's stated reason: Study never developed due to a change in business priority. | Device: GEHC IWS 4400 & Giraffe Warmer beds, GEHC IWS 4400 & Giraffe Warmer beds, GEHC IWS 4400 & Giraffe Warmer beds, GEHC IWS 4400 & Giraffe Warmer beds, GEHC IWS 4400 & Giraffe warmer beds, GEHC IWS 4400 & Giraffe Warmer beds | Body Temperature Changes | 0 | Apr 2011actual | — | 2015-09-14 |
| Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure HydrocephalusNCT01092546results2013-11-19Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the "Cerebellum" (CER) as the Reference Region.Open-label · Diagnostic | Phase 3 | Terminatedsponsor's stated reason: Changed focus of the program | Drug: [18F]Flutemetamol | Normal Pressure Hydrocephalus | 12 | Apr 2011actual | — | 2013-12-13 |
| Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult SubjectsNCT01265394results2013-06-21Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show AmyloidNon-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: [18F] Flutemetamol | Healthy | 218 | Mar 2011actual | — | 2013-07-02 |
| A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar SymptomsNCT00382967results2012-08-29Changes That the Doctor Made in the Clinical Management of Subjects Based Upon the Impact of the Imaging Product.Randomized · Open-label · Treatment | Phase 4 | Completed | Procedure: DaTSCAN SPECT imaging | Parkinsonian Syndromes | 273 | Jan 2011actual | — | 2012-09-03 |
| Technical Validation of Lunar iDXA Visceral Fat ToolNCT01110161observationalAgreement between Lunar iDXA and CT measured visceral fat of the abdominal region | — | Completed | Device: Visceral fat mass measurement | Obesity | 148 | Nov 2010actual | — | 2010-12-08 |
| Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical CareNCT00783302results2014-12-11observationalThe Sensitivity of Visipaque-enhanced Coronary Computed Tomography Angiography (CCTA) for Predicting Downstream Cardiovascular Events at Each Follow-up Period When Compared to the Standard of Truth (SoT). | — | Completed | — | Coronary Artery Disease (CAD) | 885 | Oct 2010actual | — | 2014-12-11 |
| Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder CancerNCT00634621results2014-08-25observationalDetecting the Rate of Bladder Cancer Lesions by White-Light Cystoscopy (WLC) and Blue-Light Cystoscopy (BLC) With Hexvix® in the Overall Study Population by Comparison With the Diagnostic Gold Standard, i.e. Histological Examination of Lesions Biopsy. | — | Completed | Drug: Hexaminolevulinate (Hexvix) | Bladder Cancer | 283 | Sep 2010actual | — | 2014-08-25 |
| IMPROVE Critical Care Study (Pilot)NCT01361230Proportion of time spent with low responsiveness (red colour code) during the first 48 hours in the ICURandomized · Open-label | Not applicable | Completed | Device: "Sedation Trial Monitor" is the name of the device used. | Sedated ICU Patients | 74 | Sep 2010actual | — | 2011-05-26 |
| Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).NCT00878878results2012-08-24Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a Cross-over Study.Randomized · Single-masked · Diagnostic | Phase 4 | Completed | Drug: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose | Pulmonary Hypertension | 30 | Jul 2010actual | — | 2012-08-24 |
| PET Imaging of Brain Amyloid in Normal Pressure HydrocephalusNCT01053312results2012-06-05Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.Open-label · Diagnostic | Phase 3 | Completed | Drug: [18F] Flutemetamol | Normal Pressure Hydrocephalus | 7 | Jul 2010actual | — | 2012-06-11 |
| Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat ToolNCT00987298observationalAgreement between Lunar iDXA and CT measured visceral fat of the abdominal region | — | Completed | Device: Visceral fat mass measurement | Obesity | 124 | Jun 2010actual | — | 2010-12-08 |
| Trial of Yellow Fever Inactivated VaccineNCT00995865results2016-05-05The Incidence and Severity of Adverse Events in Each Treatment Group in the Double-blind Treatment Period up to 42 Days Post-vaccination.Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: XRX-001 Inactivated yellow fever vaccine, Placebo | Yellow Fever | 60 | May 2010actual | — | 2016-05-05 |
| Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic MammographyNCT00535327observational | — | Completed | — | Breast Cancer | 220 | Mar 2010actual | — | 2010-05-14 |
| Evaluation Of The GE Monitor Product LineNCT00730119observationalThis investigation will compare values from the test device(s) to itself, or one of the reference parameters, or a combination of parameters, including NIBP, temperature, SpO2, respirations, and ECG. | — | Withdrawnsponsor's stated reason: Terminated due to lack of enrollment at target sites | — | Non-invasive Blood Pressure, Temperature, SpO2, Respiration, ECG | 0 | Mar 2010actual | — | 2017-08-08 |
| Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast BiopsyNCT00535184observational | — | Completed | — | Breast Cancer | 220 | Feb 2010actual | — | 2012-03-22 |
| Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)NCT01004770results2012-04-04Blood Urea Nitrogen and Creatinine Serum ValuesNon-randomized · Open-label · Diagnostic | Phase 1/2 | Completed | Drug: GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection | Healthy | 50 | Feb 2010actual | — | 2012-04-05 |
| Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac EventNCT00785044results2017-04-26observationalNumerical Heart to Mediastinum (H/M) Ratio at 3 Hours 50 Minutes Post-administration on Planar 123I-mIBG Imaging by Adverse Cardiac Events (ACEs) Status | — | Completed | Drug: I-123 mIBG | Congestive Heart Failure | 471 | Jan 2010actual | — | 2017-04-26 |
| A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.NCT00730964results2012-06-12The Frequency of Serious Adverse Reactions (SAR)'s Among Subjects Who Receive Optison (Causally Related to the Product)During Contrast Enhanced Echocardiography in Routine Clinical Practice.Open-label | Phase 4 | Completed | Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) | Echocardiography | 1,039 | Oct 2009actual | — | 2012-06-12 |
| Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening MammogramNCT00535678observationalCompare the diagnostic performance of FFDM and DBT in detecting and excluding breast cancer in asymptomatic women. | — | Completed | — | Breast Cancer | 400 | Jun 2009actual | — | 2010-05-14 |
| Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy VolunteersNCT00785759Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.Open-label · Diagnostic | Phase 2 | Completed | Drug: AH110690 (18F) Injection | Alzheimer's Disease, Amnestic Mild Cognitive Impairment | 78 | Mar 2009actual | — | 2009-12-07 |
| Comparative Study of Phototherapy for HyperbilirubinemiaNCT00635375The LED Fiberoptic Phototherapy System and metal halide spot phototherapy are will show no difference in therapeutic treatment times compared to the LED Bank Light System.Randomized · Open-label · Treatment | Not applicable | Completed | Device: LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy), Metal halide phototherapy (Spot PT metal halide phototherapy), LED bank phototherapy (Natus neoBlue LED bank phototherapy), Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT) | Hyperbilirubinemia | 82 | Aug 2008actual | — | 2009-01-13 |
| Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseaseNCT00126425results2016-12-13Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) RatioOpen-label · Diagnostic | Phase 3 | Completed | Drug: 123I-mIBG (meta-iodobenzylguanidine) | Heart Failure, Congestive | 587 | Jul 2008actual | — | 2016-12-13 |
| Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseaseNCT00126438results2017-05-05Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) RatioOpen-label · Diagnostic | Phase 3 | Completed | Drug: 123I-mIBG (meta-iodobenzylguanidine) | Heart Failure, Congestive | 515 | Jul 2008actual | — | 2018-03-14 |
| SuperSTAT Noninvasive Blood Pressure Monitor EvaluationNCT00603486observationalEvaluation of one of the GE DINAMAP NIBP Monitor algorithms, SuperSTAT NIBP, in neonatal and/or infant subjects. | — | Unknown status | Device: GE DINAMAP with SuperSTAT algorithm monitor | Non-Invasive Blood Pressure | 20 | May 2008actual | — | 2008-07-23 |
| Perfusion Imaging and CT -Understanding Relative EfficacyNCT00486447results2017-08-23Detection of Significant Coronary Artery Disease Using Diagnostic Catheterization for Standard of Truth.Open-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: Accrual | Device: 64 Channel VCT | Coronary Artery Disease | 249 | Apr 2008actual | — | 2017-08-23 |
| Noninvasive Blood Pressure Monitor Evaluation Including Performance During DysrhythmiasNCT00443001Comparison of early systolic, systolic, and diastolic blood pressure, MAP and pulse rate as collected by an investigational non-invasive blood pressure device versus reference standardsNon-randomized · Open-label · Diagnostic | Not applicable | Completed | Device: Non invasive blood pressure monitor | Healthy | 40 | Jul 2007actual | — | 2022-07-27 |
| A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest PainNCT00348569Open-label · Diagnostic | Not applicable | Completed | Device: 64 Channel VCT | Coronary Artery Disease | 245 | 2007-01-31actual | — | 2019-04-29 |
| Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartNCT00335335To evaluate diagnostic performance and safety of Visipaque-enhanced CTA images for determination of presence or absence of coronary artery obstructionNon-randomized · Open-label · Diagnostic | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision due to low subject recrcuitment | Drug: iodixanol | Coronary Artery Disease | 89 | 2006-12-02actual | — | 2019-04-25 |
| Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartNCT00348608To evaluate diagnostic performance and safety of Visipaque-enhanced CTA images for determination of presence or absence of coronary artery obstructionNon-randomized · Open-label · Diagnostic | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision (due to low subject recruitment) | Drug: iodixanol | Coronary Artery Disease | 66 | 2006-12-02actual | — | 2019-04-25 |
| A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCTNCT00350506Open-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: Sponsor decision (due to low subject enrollment) | Device: 64 Channel VCT | Coronary Artery Disease | 77 | Oct 2006actual | — | 2019-04-30 |
| Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaNCT00126412- To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.Open-label · Diagnostic | Phase 3 | Completed | Drug: 123I-mIBG (meta-iodobenzylguanidine) | Pheochromocytoma, Neuroblastoma | 251 | 2006-09-27actual | — | 2019-05-31 |
| A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using GadodiamideNCT00209443Differences in subject level and vessel level sensitivity and specificity between CE-MRA and TOF-MRA in detecting stenosis,(>50% occlusion) in aorto-iliac arteries. IA-DSA is the truth standard.Non-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: Gadodiamide Injection | Aorto-iliac Stenosis, Arterial Occlusive Diseases | 407 | 2006-02-28actual | — | 2019-04-25 |
| A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using GadodiamideNCT00209391Subject level efficacy of CE-MRA in detecting stenosis (50% occlusion) of major renal arteries. IA-DSA is the truth standard.Non-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: Gadodiamide Injection | Renal Artery Stenosis | 395 | 2005-08-01actual | — | 2019-04-25 |
| Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)NCT00209404Change in mean heart rateNon-randomized · Open-label · Diagnostic | Phase 4 | Completed | Drug: Iodixanol 320 mg I/Ml | Coronary Artery Disease | 50 | — | — | 2007-10-31 |
| Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary AngiographyNCT00209430Peak increase in SCrRandomized · Double-masked · Diagnostic | Phase 4 | Completed | Drug: Iodixanol 320 mgI/mL | Coronary Artery Disease, Renal Impairment | 408 | — | — | 2007-10-31 |
| Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body DementiaNCT00209456Sensitivity and specificity of DaTSCAN SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects.Non-randomized · Open-label · Diagnostic | Phase 3 | Completed | Drug: DatSCAN | Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia | 326 | — | — | 2007-05-16 |
| Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary AngiographyNCT00335101Primary endpoint:Randomized · Double-masked · Diagnostic | Phase 4 | Withdrawnsponsor's stated reason: Sponsor Decision to withdraw study (comparative product withdrawn from the market) | Drug: Iodixanol, Ioversol, Iopromide | Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus | 0 | — | — | 2019-04-29 |
| Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition ApproachesNCT00381316The diagnostic results ("normal" versus "abnormal") of the dual-isotope and single isotope myocardial SPECT examinations will be compared for equivalence on a subject level for the Uninformed and Informed Analysis Groups.Non-randomized · Open-label · Diagnostic | Phase 4 | Completed | Drug: Technetium Tc99m Tetrofosmin injections, Thallous Chloride T1-201 | Coronary Artery Disease | 291 | — | — | 2007-12-05 |
| Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep StagesNCT00712946observational | — | Completed | — | Arteriosclerosis Obliterans | 103 | — | — | 2011-04-28 |
| Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected NeuroblastomaNCT00730444expanded access | — | Approved for marketing | Drug: Iobenguane I 123 Injection | Neuroblastoma | — | — | — | 2009-11-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19